IPNews® – The Federal Circuit on Tuesday partially reversed a lower court’s finding that a number of Santarus Inc.’s patent claims for its heartburn drug Zegerid are invalid, giving Santarus another crack at hanging Par Pharmaceuticals Inc. out to dry for trying to market a generic version of the drug.

The district court slipped up when it ruled that some of the thirty-six asserted claims would have been obvious over the prior art, the appeals court said. The Federal Circuit affirmed the lower court’s finding that there was no inequitable conduct. To continue reading, click: Federal Circuit Revives Some Santarus Generic Zegerid Patent Claims V. Par